Richard Alistair  Stewart net worth and biography

Richard Stewart Biography and Net Worth

Mr. Stewart is a co-founder of Achieve and previously served as the Company’s President and Chief Executive Officer. He is a director on the Achieve Board of Directors and previously served as Chairman. Mr. Stewart is also a founder and a director of Ricanto Limited, a pharmaceutical asset optimization company, since 2009. Mr. Stewart has been Chairman and Chief Executive Officer of Renown Pharma Limited, a central nervous system company focused on Parkinson’s disease, since 2016. Prior to Achieve, Mr. Stewart was Chairman and Chief Executive Officer of Huxley Pharmaceuticals, Inc., a single-purpose central nervous system company, during 2009, prior to Huxley Pharmaceuticals, Inc.’s acquisition by BioMarin Pharmaceutical Inc. Mr. Stewart was Chief Executive Officer of Brabant Pharma Limited, a single-purpose central nervous system company, from 2013 to 2014 prior to Brabant Pharma’s acquisition by Zogenix Inc. He was a co-founder and Chief Executive Officer of Amarin Corporation plc, a central nervous system company focused on Parkinson’s disease and Huntington’s disease, from 2000 to 2007. Mr. Stewart was a co-founder and Chief Financial Officer, and later Chief Business Officer, of SkyePharma plc, a drug delivery company specializing in controlled release formulations, and held such positions from 1995 to 1998. Mr. Stewart holds a Bachelor of Science degree in Business Administration from the University of Bath.

What is Richard Alistair Stewart's net worth?

The estimated net worth of Richard Alistair Stewart is at least $1.28 million as of September 18th, 2025. Stewart owns 228,875 shares of Achieve Life Sciences stock worth more than $1,281,700 as of June 9th. This net worth estimate does not reflect any other assets that Stewart may own. Learn More about Richard Alistair Stewart's net worth.

How do I contact Richard Alistair Stewart?

The corporate mailing address for Stewart and other Achieve Life Sciences executives is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. Achieve Life Sciences can also be reached via phone at (604) 210-2217 and via email at [email protected]. Learn More on Richard Alistair Stewart's contact information.

Has Richard Alistair Stewart been buying or selling shares of Achieve Life Sciences?

Richard Alistair Stewart has not been actively trading shares of Achieve Life Sciences during the past quarter. Most recently, Richard Alistair Stewart sold 129,501 shares of the business's stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $2.92, for a transaction totalling $378,142.92. Following the completion of the sale, the chief executive officer now directly owns 228,875 shares of the company's stock, valued at $668,315. Learn More on Richard Alistair Stewart's trading history.

Who are Achieve Life Sciences' active insiders?

Achieve Life Sciences' insider roster includes John Bencich (CEO), and Richard Stewart (CEO). Learn More on Achieve Life Sciences' active insiders.

Are insiders buying or selling shares of Achieve Life Sciences?

During the last twelve months, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 381,972 shares worth more than $1,084,996.59. The most recent insider tranaction occured on September, 18th when CFO Mark K Oki sold 50,060 shares worth more than $146,175.20. Insiders at Achieve Life Sciences own 3.0% of the company. Learn More about insider trades at Achieve Life Sciences.

Information on this page was last updated on 9/18/2025.

Richard Alistair Stewart Insider Trading History at Achieve Life Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/18/2025Sell129,501$2.92$378,142.92228,875View SEC Filing Icon  
5/23/2019Buy17,500$3.61$63,175.00View SEC Filing Icon  
See Full Table

Richard Alistair Stewart Buying and Selling Activity at Achieve Life Sciences

This chart shows Richard Alistair Stewart's buying and selling at Achieve Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Achieve Life Sciences Company Overview

Achieve Life Sciences logo
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
Read More

Today's Range

Now: $5.60
Low: $5.36
High: $5.74

50 Day Range

MA: $4.39
Low: $2.65
High: $5.99

2 Week Range

Now: $5.60
Low: $2.00
High: $6.15

Volume

1,191,105 shs

Average Volume

1,033,194 shs

Market Capitalization

$574.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.27